ReviewACS nano2024
Research Advances of Cellular Nanoparticles as Multiplex Countermeasures.
Review in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Intelligent Programmable Membrane Nanosponge for Early Virus Blocking.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mesenchymal Stromal Cell-Based Cell-Drug Conjugates for the Treatment of Acute Liver Failure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in nano-delivery systems for overcoming the challenges of applying siRNA drugs in tumor therapy.Asian journal of pharmaceutical sciences · 2026Review
- Cell Membrane-Coated Nanoparticles: Advanced Drug Delivery Systems for Chronic Wound Healing Therapy.International journal of nanomedicine · 2026Review
- Article
- Neutrophil-Mimicking Prussian blue nanozymes for synergistic targeted immuno-metabolic therapy of hepatic ischemia-reperfusion injury.Journal of nanobiotechnology · 2025Article
- Nature-Inspired Nanostructures from Multiple-Species Biomembranes: Rational Engineering and Therapeutic Applications in Tumor-Targeted Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Smart biomimetic "nano-med-fireman" blocking inflammation and lactate metabolism crosstalk for normalized spatiotemporal photo-immunotherapy.Bioactive materials · 2025Article
- Advancements in Tumor-Targeted Nanoparticles: Design Strategies and Multifunctional Therapeutic Approaches.Nanomaterials (Basel, Switzerland) · 2025Review
- Nanoparticle technologies for liver targeting and their applications in liver diseases.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cellular nanoparticles (CNPs), fabricated by coating natural cell membranes onto nanoparticle cores, have been widely used to replicate cellular functions for various therapeutic applications. Specifically, CNPs act as cell decoys, binding harmful molecules or infectious pathogens and neutralizing their bioactivity. This neutralization strategy leverages the target's functional properties rather than its structure, resulting in broad-spectrum efficacy. Since their inception, CNP platforms have undergone significant advancements to enhance their neutralizing capabilities and efficiency. This review traces the research advances of CNP technology as multiplex countermeasures across four categories with progressive functions: neutralization through cell membrane binding, simultaneous neutralization using both cell membrane and nanoparticle core, continuous neutralization via enzymatic degradation, and enhanced neutralization through membrane modification. The review highlights the structure-property relationship in CNP designs, showing the functional advances of each category of CNP. By providing an overview of CNPs in multiplex neutralization of a wide range of chemical and biological threat agents, this article aims to inspire the development of more advanced CNP nanoformulations and uncover innovative applications to address unresolved medical challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.